Antihypertensive pharmacogenetics: Getting the right drug into the right patient

Journal of Hypertension

Volumn 19, Issue 1, 2001, Pages 1-11

  Turner, Stephen T ^a,b,c   Schwartz, Gary L ^a,b,c   Chapman, Arlene B ^a,b,c   Hall, W Dallas ^a,b,c   Boerwinkle, Eric ^a,b,c  

^a MAYO CLINIC   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Blood pressure; Genetics; Hypertension; Pharmacology

Indexed keywords

ACYLTRANSFERASE; ADDUCIN; ALPRENOLOL; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFURALOL; CALCIUM CHANNEL BLOCKING AGENT; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 2D6; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLIZING ENZYME; ENCAINIDE; FLECAINIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDRALAZINE; METHYLDOPA; METOPROLOL; MEXILETINE; PHENYLEPHRINE; PROPRANOLOL; THIAZIDE DIURETIC AGENT; TIMOLOL; UNINDEXED DRUG;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; DNA POLYMORPHISM; DRUG METABOLISM; DRUG RESPONSE; GENETIC VARIABILITY; GENOME; HUMAN; HYPERTENSION; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

EID: 0035142270     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200101000-00001     Document Type: Review

References (161)

1. Drug reactions, enzymes and biochemical genetics
2. Moderne probleme der humangenetik
3. Drugs in special patient groups: Clinical importance of genetics in drug effects
4. Shattuck lecture - Medical and societal consequences of the human genome project
5. Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension
6. Polymorphisms of a-adducin and salt sensitivity in patients with essential hypertension
7. Association of a human G-protein B3 subunit variant with hypertension
8. Linkage and association of adrenergic and dopamine receptor genes in the distal portion of the long arm of chromosome 5 with systolic blood pressure variation
9. One cause? Many causes? The argument from the bimodal distribution
10. Blood pressure regulation: Basic concepts
11. Evaluation of the hypertensive patient with emphasis on detecting curable causes
12. Hypertension in a family practice
13. Secondary hypertension in a blood pressure clinic
14. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo
15. Department of veterans affairs single drug therapy of hypertension study. Revised figures and new data
16. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril, and nifedipine
17. Individual responses to converting enzyme inhibitors and calcium antagonists
18. The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies
19. Predicting interindividual variations in antihypertensive therapy: The role of sodium transport systems and renin
20. Individualizing antihypertensive therapy with enalapril versus atenolol: The Zurich experience
21. Comparison of betaxolol with verapamil in hypertensive patients: Discrepancy between office and ambulatory blood pressures
22. Double blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents; preliminary results
23. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug
24. Optimization of antihypertensive treatment by crossover rotation of four major classes
25. Pathophysiology of hypertension and treatment
26. Relation between initial blood pressure and its fall with treatment
27. Initial blood pressure as a predictor of the response to antihypertensive therapy
28. Pharmacologic therapy of hypertension in blacks
29. The impact of ethnicity on response to antihypertensive therapy
30. Varying responses to hypotensive agents in different racial groups: Black versus white differences
31. Critical comments on recent literature. Age and the response to antihypertensive drugs
32. Comparative studies in hypertension: Some fallacious claims of age-related drug efficacy
33. Hypertension, obesity and response to antihypertensive treatment: Results of a community survey
34. Hypertension in women: Current understanding of gender differences
35. Diagnosis Ex Juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment
36. Renin system analysis: A rational method for the diagnosis and treatment of the individual patient with hypertension
37. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients
38. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy
39. Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system
40. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure
41. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
42. Polymorphic hydroxylation of debrisoquine in man
43. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
44. Nomenclature for human CYP2D6 alleles
45. Debrisoquine hydroxylase genotype and phenotype
46. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population
47. Ethnic difference in drug metabolism: Debrisoquine 4-hydroxylation in caucasians and orientals
48. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
49. High plasma concentrations of B-receptor blocking drugs and deficient debrisoquine hydroxylation
50. Oxidation phenotype - A major determinant of metoprolol metabolism and response
51. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine
52. Beta-blockers and drug oxidation status
53. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents
54. Chronic dosing comparison of three formulations of metoprolol and atenolol in hypertensive patients
55. Clinical implications of variable anti-arrhythmic drug metabolism
56. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis
57. Pharmacogenetics: A laboratory tool for optimizing therapeutic efficiency
58. Isolation and mapping of a cosmid clone containing the human NAT2 gene
59. Chromosomal localization of human genes for arylamine N-acetyltransferase
60. Genetic factors influencing isoniazid blood levels in humans
61. Genetics of isoniazid metabolism in Caucasians, Negro, and Japanese populations
62. Human acetylator polymorphism: Estimates of allele frequency in Libya and details of global distribution
63. Genetical and geographic studies on isoniazid inactivation
64. Further observations on trimodality of frequency distribution curve of biologically active isoniazid blood levels and 'cline' in frequencies of alleles controlling isoniazid inactivation
65. Relation of hydralazine plasma concentration to dosage and hypotensive action
66. Acetylator phenotype and the antihypertensive response to hydralazine
67. Plasma concentration and acetylator phenotype determine response to oral hydralazine
68. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis
69. Acetylator phenotype and lupus erythematosus
70. Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex on susceptibility
71. Inheritance of low erythrocyte catechol-o-methyltransferase activity in man
72. Methyltransferase pharmacogenetics
73. Methylation pharmacogenetics: Catechol-o-methyltransferase, thiopurine methyltransferase, and histamine n-methyltransferase
74. Platelet phenol sulfotransferase and erythrocyte catechol-o-methyltransferase activities: Correlation with methyldopa metabolism
75. Sulfate and methyldopa metabolism: Metabolite patterns and platelet phenol sulfotransferase activity
76. Identification of the possible molecular basis for inherited differences in human catechol-O-methyltransferase
77. Human catechol O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders
78. Genetics of red cell COMT activity: Analysis of thermal stability and family data
79. Withdrawal of posicor from market
80. In vitro techniques for studying drug metabolism
81. Pharmacogenetics: Its biologic roots and the medical challenge
82. Treatment of hypertension: Drug therapy
83. Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man
84. Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension
85. Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug
86. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension
87. Are there differences among angiotensin receptor blockers?
88. Comparative antihypertensive effects of angiotensin II receptor antagonists
89. Comparison of acebutolol and propranolol in essential hypertension
90. Choosing the right ACE inhibitor. A guide to selection
91. The effect of withdrawing antihypertensive therapy: A review
92. A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people
93. Do we need more anti-hypertensive drugs: Lessons from the new biology
94. Pharmacogenomics: A new approach to individual therapy of hypertension?
95. Two point mutations within the adducin gene are involved in blood pressure variation
96. Hypertension-association point mutations in the adducin a and B subunits affect actin cytoskeleton and ion transport
97. Adducin in essential hypertension
98. The role of a-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study
99. Pathophysiologic effects and strategies for long-term diuretic treatment of hypertension
100. A comprehensive review of the salt and blood pressure relationship
101. Renin system activity as a determinant of response to treatment in hypertension and heart failure
102. An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients
103. The serum angiotensin concentration and variants of the angiotensinogen gene in white and black children
104. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro
105. Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene Hypertension
106. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
107. Inherited forms of mineralocorticoid hypertension
108. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension. Trials of hypertension prevention, phase II
109. Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene
110. Angiotensin I-converting enzyme gene polymorphism and salt sensitivity in essential hypertension
111. Angiotensinogen M235T variant and salt sensitivity in young normotensive Caucasians
112. The association between salt sensitivity of blood pressure and some polymorphic factors
113. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition
114. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes
115. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies
116. Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria
117. s gene with essential hypertension and response to B-blockade
118. Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough
119. Three candidate genes and angiotensin-converting enzyme inhibitor-related cough
120. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects
121. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension
122. Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy
123. Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism
124. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy
125. Angiotensin-converting enzyme gene polymorphism determines the anti-proteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease
126. ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients
127. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: Role of sodium status
128. Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy
129. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy
130. Angiotensin II type 1 receptor gene polymorphism is associated with an increased vascular reactivity in the human mammary artery in vitro
131. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals
132. Positional cloning: Let's not call it reverse anymore
133. Positional cloning moves from perditional to traditional
134. Microsatellites for linkage analysis of genetic traits
135. A pharmacogenetic approach to blood pressure in Lyon hypertensive rats
136. Ionic disturbances of calcium and magnesium metabolism in essential hypertension
137. How many genes in the human genome?
138. Variations on a theme: Cataloging human DNA sequence variation
139. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome
140. The use of a genetic map of biallelic markers in linkage studies
141. The future of genetic studies of complex human diseases
142. Biochips: An evolving clinical technology
143. Powerful tools for genetic analysis come of age
144. DNA chip technology ante portas
145. Bioinformatics in the pharmaceutical industry
146. The use of genetic information in large-scale clinical trials: Applications of alzheimer research
147. Genetics and the drug response
148. Computational genomics: Medicine of the future?
149. Biotechnologies to watch. Which technologies promise to make significant contributions to biotechnology's drug pipeline?
150. The business of pharmacogenomics. Considered the heir apparent to functional genomics, pharmacogenomics promises to redefine basic notions of what constitutes a disease
151. Millenium exploits retained right with new venture
152. Phase II results in rheumatoid arthritis encouraging for Immunex
153. Genetic epidemiology of coronary artery disease
154. Field of needs. The genetics of stroke
155. Susceptibility genes for end-organ damage. New strategies to understand diabetic and hypertensive nephropathy
156. How will knowledge of the human genome affect drug therapy?
157. Genomics in the real world
158. Human genome studies expected to revolutionize cancer classification
159. The impact of pharmacogenetics on the future of healthcare
160. Pharmacogenomics: Translating functional genomics into rational therapeutics